Document Detail


A comparison of mortality, myocardial infarction, and repeated revascularization for sirolimus-eluting and paclitaxel-eluting coronary stents.
MedLine Citation:
PMID:  17719304     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Drug-eluting stents are now used in most percutaneous coronary interventions. There are only 2 approved devices: sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). Only a few population-based studies have compared their patient outcomes. METHODS: All New York State patients undergoing SES or PES in nonfederal hospitals in the state between April 1 and December 31, 2004, except those with a previous revascularization, left main coronary artery disease, or a recent myocardial infarction (MI) or shock (4867 patients with PES and 6914 with SES) were followed up through the end of 2005. We compared SES and PES with respect to inhospital and 18-month mortality, 18-month mortality/MI, and subsequent target vessel and target lesion revascularization (TVR and TLR) after adjusting for differences in patient risk factors. RESULTS: By 18 months after receiving a PES, 4.0% of the patients died compared with 4.1% for SES patients, 5.9% of PES patients experienced mortality/MI compared with 6.3% of SES patients, 6.8% of the PES patients had a subsequent TVR within 18 months compared with 7.8% for SES patients, and 4.5% of the PES patients had a subsequent TLR within 18 months compared with 5.3% for SES patients. The respective adjusted hazards ratios (PES/SES) for these adverse outcomes were 1.02 (95% CI 0.82-1.26, P = .86), 0.94 (95% CI 0.78-1.13, P = .52), 0.89 (95% CI 0.75-1.06, P = .20), and 0.86 (95% CI 0.70-1.05, P = .14). CONCLUSIONS: Patients receiving PES and SES do not have significantly different 18-month mortality, mortality/MI, subsequent TVR, or subsequent TLR rates.
Authors:
Edward L Hannan; Michael Racz; David R Holmes; Samin Sharma; Stanley Katz; Gary Walford; Spencer B King; Luther T Clark; Robert H Jones
Related Documents :
10860094 - Erectile dysfunction, sildenafil and cardiovascular risk.
12588224 - Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort stud...
18360044 - High prevalence of chronic kidney disease among patients with sleep related breathing d...
16047354 - Risk factors for diabetes insipidus in langerhans cell histiocytosis.
17072964 - Diagnostic dilemma of abdominal tuberculosis in non-hiv patients: an ongoing challenge ...
7912394 - Inhibition of human vascular smooth muscle cell growth by heparin.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  154     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-08-27     Completed Date:  2007-09-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  545-53     Citation Subset:  AIM; IM    
Affiliation:
School of Public Health, University at Albany, State University of New York, Albany, NY 12144-3456, USA. elh03@health.state.ny.us
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Coronary Vessels*
Drug Delivery Systems*
Female
Humans
Male
Middle Aged
Myocardial Infarction / mortality*,  therapy*
Myocardial Revascularization / methods,  statistics & numerical data
Paclitaxel / administration & dosage*
Sirolimus / administration & dosage*
Stents*
Chemical
Reg. No./Substance:
33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy...
Next Document:  Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among th...